Mechanisms of tubulin binding ligands to target cancer cells: Updates on their therapeutic potential and clinical trials

Current Cancer Drug Targets

Volumn 17, Issue 4, 2017, Pages 357-375

  Kumar, Bhupinder ^a   Kumar, Rakesh ^a   Skvortsova, Ira ^b   Kumar, Vinod ^a  

^a CENTRAL UNIVERSITY OF PUNJAB   (India)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Anticancer; Combination therapy; Microtubule stabilizing agents; Tubulin binding ligands; Tubulin inhibitor; Tubulin polymerization depolymerization

Indexed keywords

6 METHOXY 2 METHYL 3 (3,4,5 TRIMETHOXYBENZOYL)BENZOFURAN 7 YL PHOSPHATE DISODIUM; ANETUMAB RAVTANSINE; COLCHICINE; COLTUXIMAB RAVTANSINE; COMBRETASTATIN A1 PHOSPHATE; COMBRETASTATIN A4 PHOSPHATE; LEXIBULIN; N [2 [(4 HYDROXYPHENYL)AMINO] 3 PYRIDINYL] 4 METHOXYBENZENESULFONAMIDE; OMBRABULIN; PLINABULIN; TRASTUZUMAB EMTANSINE; TUBULIN; VERUBULIN; VINBLASTINE; VINCRISTINE; LIGAND;

APOPTOSIS; BINDING AFFINITY; CANCER CHEMOTHERAPY; CARCINOGENIC ACTIVITY; CELL MIGRATION; CELL SIGNALING ASSAY; CELL TRANSPORT; CLINICAL PRACTICE; CYTOTOXICITY; HUMAN; IMMUNOFLUORESCENCE; MASS SPECTROMETRY; NEUROTOXICITY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; NUCLEOTIDE BINDING SITE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHENOTYPE; POLYMERIZATION; REVIEW; X RAY CRYSTALLOGRAPHY; BINDING SITE; DRUG EFFECTS; METABOLISM; MICROTUBULE; NEOPLASM; PATHOLOGY;

BINDING SITES; HUMANS; LIGANDS; MICROTUBULES; NEOPLASMS; POLYMERIZATION; TUBULIN;

EID: 85020869828     PISSN: 15680096     EISSN: 18735576     Source Type: Journal    
DOI: 10.2174/1568009616666160928110818     Document Type: Review

References (137)

1. Dustin, P. Microtubules; Springer Verlag: Berlin, Heidelberg, New York, 1978, vol. 452.
2. Nogales, E.; Wolf, S.G.; Downing, K.H. Structure of the a p tubulin dimer by electron crystallography. Nature, 1998, 391(6663), 199-203.
3. Mitchison, T.; Kirschner, M. Dynamic instability of microtubule growth. Nature, 1984, 312(5991), 237-242.
4. Huzil, J.T.; Chen, K.; Kurgan, L.; Tuszynski, J.A. The roles of β-tubulin mutations and isotype expression in acquired drug resistance. Cancer Inform., 2007, 3, 159-181.
5. Vandecandelaere, A.; Brune, M.; Webb, M.R.; Martin, S.R.; Bayley, P.M. Phosphate release during microtubule assembly: what stabilizes growing microtubules? Biochemistry, 1999, 38(25), 8179-8188.
6. Joshi, H.C.; Palacios, M.J.; McNamara, L.; Cleveland, D.W. γ-tubulin is a centrosomal protein required for cell cycle-dependent microtubule nucleation. Nature, 1992, 356(6364), 80-83.
7. Moritz, M.; Agard, D.A. γ-tubulin complexes and microtubule nucleation. Curr. Opin. Struct. Biol., 2001, 11(2), 174-181.
8. Dutcher, S.K.; Trabuco, E.C. The UN13 gene is required for assembly of basal bodies of Chlamydomonas and encodes 8-tubulin, a new member of the tubulin superfamily. Mol. Biol. Cell, 1998, 9(6), 1293-1308.
9. Inclan, Y.F.; Nogales, E. Structural models for the self-assembly and microtubule interactions of gamma-, delta- and epsilon-tubulin. J. Cell Sci., 2001, 114(Pt 2), 413-422.
10. Chang, P.; Stearns, T. γ-tubulin and epsilon-tubulin: two new human centrosomal tubulins reveal new aspects of centrosome structure and function. Nat. Cell Biol., 2000, 2(1), 30-35.
11. Kaur, R.; Dwivedi, A.R.; Kumar, B.; Kumar, V. Recent developments on 1, 2, 4-triazole nucleus in anticancer compounds: a review. Anticancer Agents Med. Chem., 2016, 16(4), 465-489.
12. Rohena, C.C.; Mooberry, S.L. Recent progress with microtubule stabilizers: new compounds, binding modes and cellular activities. Nat. Prod. Rep., 2014, 31(3), 335-355.
13. Risinger, A.L.; Giles, F.J.; Mooberry, S.L. Microtubule dynamics as a target in oncology. Cancer Treat. Rev., 2009, 35(3), 255-261.
14. Carlson, R.O. New tubulin targeting agents currently in clinical development. Expert Opin. Investig. Drugs, 2008, 17(5), 707-722.
15. Altmann, K.-H.; Gertsch, J. Anticancer drugs from naturenatural products as a unique source of new microtubule-stabilizing agents. Nat. Prod. Rep., 2007, 24(2), 327-357.
16. Jordan, M.A.; Wilson, L. Microtubules as a target for anticancer drugs. Nat. Rev. Cancer, 2004, 4(4), 253-265.
17. Liu, Y.-M.; Chen, H.-L.; Lee, H.-Y.; Liou, J.-P. Tubulin inhibitors: a patent review. Expert Opin. Ther. Pat., 2014, 24(1), 69-88.
18. Wilmes, A.; Bargh, K.; Kelly, C.; Northcote, P.T.; Miller, J.H. Peloruside A synergizes with other microtubule stabilizing agents in cultured cancer cell lines. Mot. Pharm., 2007, 4(2), 269-280.
19. Howard, J.; Hyman, A.A. Dynamics and mechanics of the microtubule plus end. Nature, 2003, 422(6933), 753-758.
20. Nettles, J.H.; Li, H.; Cornett, B.; Krahn, J.M.; Snyder, J.P.; Downing, K.H. The binding mode of epothilone A on a, beta-tubulin by electron crystallography. Science, 2004, 305(5685), 866-869.
21. Pryor, D.E.; O’Brate, A.; Bilcer, G.; Diaz, J.F.; Wang, Y.; Wang, Y.; Kabaki, M.; Jung, M.K.; Andreu, J.M.; Ghosh, A.K.; Giannakakou, P.; Hamel, E. The microtubule stabilizing agent laulimalide does not bind in the taxoid site, kills cells resistant to paclitaxel and epothilones, and may not require its epoxide moiety for activity. Biochemistry, 2002, 41(29), 9109-9115.
22. Gaitanos, T.N.; Buey, R.M.; Diaz, J.F.; Northcote, P.T.; Teesdale Spittle, P.; Andreu, J.M.; Miller, J.H. Peloruside A does not bind to the taxoid site on β-tubulin and retains its activity in multidrug-resistant cell lines. Cancer Res., 2004, 64(15), 5063-5067.
23. Liu, J.; Towle, M.J.; Cheng, H.; Saxton, P.; Reardon, C.; Wu, J.; Murphy, E.A.; Kuznetsov, G.; Johannes, C.W.; Tremblay, M.R.; Zhao, H.; Pesant, M.; Fang, F.G.; Vermeulen, M.W.; Gallagher, B. M., Jr; Littlefield, B.A. In vitro and in vivo anticancer activities of synthetic (-)-laulimalide, a marine natural product microtubule stabilizing agent. Anticancer Res., 2007, 27(3B), 1509-1518.
24. Skoufias, D.A.; Wilson, L. Mechanism of inhibition of microtubule polymerization by colchicine: inhibitory potencies of unliganded colchicine and tubulin-colchicine complexes. Biochemistry, 1992, 31(3), 738-746.
25. Westermann, S.; Weber, K. Post-translational modifications regulate microtubule function. Nat. Rev. Mol. Cell Biol., 2003, 4(12), 938-947.
26. Mozzetti, S.; Ferlini, C.; Concolino, P.; Filippetti, F.; Raspaglio, G.; Prislei, S.; Gallo, D.; Martinelli, E.; Ranelletti, F.O.; Ferrandina, G.; Scambia, G. Class III β-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients. Clin. Cancer Res., 2005, 11(1), 298-305.
27. Katsetos, C.D.; Draber, P. Tubulins as therapeutic targets in cancer: from bench to bedside. Curr. Pharm. Des., 2012, 18(19), 2778-2792.
28. Liu, B.; Staren, E.D.; Iwamura, T.; Appert, H.E.; Howard, J.M. Mechanisms of taxotere-related drug resistance in pancreatic carcinoma. J. Surg. Res., 2001, 99(2), 179-186.
29. Katsetos, C.D.; Herman, M.M.; Mork, S.J. Class III β-tubulin in human development and cancer. Cell Motil. Cytoskelet., 2003, 55(2), 77-96.
30. Shalli, K.; Brown, I.; Heys, S.D.; Schofield, A.C. Alterations of β-tubulin isotypes in breast cancer cells resistant to docetaxel. FASEB J., 2005, 19(10), 1299-1301.
31. Karki, R.; Mariani, M.; Andreoli, M.; He, S.; Scambia, G.; Shahabi, S.; Ferlini, C. pIII-Tubulin: biomarker of taxane resistance or drug target? Expert Opin. Ther. Targets, 2013, 17(4), 461-472.
32. McCarroll, J.A.; Gan, P.P.; Liu, M.; Kavallaris, M. betaIII-tubulin is a multifunctional protein involved in drug sensitivity and tumorigenesis in non-small cell lung cancer. Cancer Res., 2010, 70(12), 4995-5003.
33. Kavallaris, M. Microtubules and resistance to tubulin-binding agents. Nat. Rev. Cancer, 2010, 10(3), 194-204.
34. De Donato, M.; Mariani, M.; Petrella, L.; Martinelli, E.; Zannoni, G. F.; Vellone, V.; Ferrandina, G.; Shahabi, S.; Scambia, G.; Ferlini, C. Class III β-tubulin and the cytoskeletal gateway for drug resistance in ovarian cancer. J. Cell. Physiol., 2012, 227(3), 1034-1041.
35. Gan, P.P.; Pasquier, E.; Kavallaris, M. Class III β-tubulin mediates sensitivity to chemotherapeutic drugs in non small cell lung cancer. Cancer Res., 2007, 67(19), 9356-9363.
36. Katsetos, C.D.; Reginato, M.J.; Baas, P.W.; D’Agostino, L.; Legido, A.; Tuszyn Ski, J.A.; Dráberová, E.; Dráber, P. Emerging microtubule targets in glioma therapy. Semin. Pediatr. Neurol., 2015, 22(1), 49-72.
37. Ferguson, R.E.; Taylor, C.; Stanley, A.; Butler, E.; Joyce, A.; Harnden, P.; Patel, P.M.; Selby, P.J.; Banks, R.E. Resistance to the tubulin-binding agents in renal cell carcinoma: no mutations in the class I β-tubulin gene but changes in tubulin isotype protein expression. Clin. Cancer Res., 2005, 77(9), 3439-3445.
38. Hasegawa, S.; Miyoshi, Y.; Egawa, C.; Ishitobi, M.; Tamaki, Y.; Monden, M.; Noguchi, S. Mutational analysis of the class I β-tubulin gene in human breast cancer. Int. J. Cancer, 2002, 707(1), 46-51.
39. Hari, M.; Wang, Y.; Veeraraghavan, S.; Cabral, F. Mutations in α- and β-tubulin that stabilize microtubules and confer resistance to colcemid and vinblastine. Mol. Cancer Ther., 2003, 2(7), 597-605.
40. Kavallaris, M.; Tait, A.S.; Walsh, B.J.; He, L.; Horwitz, S.B.; Norris, M.D.; Haber, M. Multiple microtubule alterations are associated with Vinca alkaloid resistance in human leukemia cells. Cancer Res., 2001, 67(15), 5803-5809.
41. Schiff, P.B.; Fant, J.; Horwitz, S.B. Promotion of microtubule assembly in vitro by taxol. Nature, 1979, 277(5698), 665-667.
42. Díaz, J.F.; Menéndez, M.; Andreu, J.M. Thermodynamics of ligand-induced assembly of tubulin. Biochemistry, 1993, 52(38), 10067-10077.
43. Canales, A.; Rodríguez-Salarichs, J.; Trigili, C.; Nieto, L.; Coderch, C.; Andreu, J.M.; Paterson, I.; Jiménez-Barbero, J.; Díaz, J.F. Insights into the interaction of discodermolide and docetaxel with tubulin. Mapping the binding sites of microtubule-stabilizing agents by using an integrated NMR and computational approach. ACS Chem. Biol., 2011, 6(8), 789-799.
44. Prota, A.E.; Bargsten, K.; Zurwerra, D.; Field, J.J.; Díaz, J.F.; Altmann, K.-H.; Steinmetz, M.O. Molecular mechanism of action of microtubule-stabilizing anticancer agents. Science, 2013, 339(6119), 587-590.
45. Matesanz, R.; Rodríguez-Salarichs, J.; Pera, B.; Canales, A.; Andreu, J.M.; Jiménez-Barbero, J.; Bras, W.; Nogales, A.; Fang, WS.; Díaz, J.F. Modulation of microtubule interprotofilament interactions by modified taxanes. Biophys. J., 2011, 707(12), 2970-2980.
46. Sui, H.; Downing, K.H. Structural basis of interprotofilament interaction and lateral deformation of microtubules. Structure, 2010, 78(8), 1022-1031.
47. Elie-Caille, C.; Severin, F.; Helenius, J.; Howard, J.; Muller, D.J.; Hyman, A.A. Straight GDP-tubulin protofilaments form in the presence of taxol. Curr. Biol., 2007, 77(20), 1765-1770.
48. Nogales, E.; Whittaker, M.; Milligan, R.A.; Downing, K.H. Highresolution model of the microtubule. Cell, 1999, 96(1), 79-88.
49. Mitra, A.; Sept, D. Taxol allosterically alters the dynamics of the tubulin dimer and increases the flexibility of microtubules. Biophys. J., 2008, 95(7), 3252-3258.
50. Bollag, D.M.; McQueney, P.A.; Zhu, J.; Hensens, O.; Koupal, L.; Liesch, J.; Goetz, M.; Lazarides, E.; Woods, C.M. Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. Cancer Res., 1995, 55(11), 2325-2333.
51. Grant, C.; Rahman, F.; Piekarz, R.; Peer, C.; Frye, R.; Robey, R.W.; Gardner, E.R.; Figg, W.D.; Bates, S.E. Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors. Expert Rev. Anticancer Ther., 2010, 70(7), 997-1008.
52. Kowalski, R.J.; Giannakakou, P.; Hamel, E. Activities of the microtubule-stabilizing agents epothilones A and B with purified tubulin and in cells resistant to paclitaxel (Taxol(R)). J. Biol. Chem., 1997, 272(4), 2534-2541.
53. Son, D.J.; Jung, J.C.; Hong, J.T. Epothilones suppress neointimal thickening in the rat carotid balloon-injury model by inducing vascular smooth muscle cell apoptosis through p53-dependent signaling pathway. PLoS One, 2016, 77(5), e0155859.
54. Cheng, K.L.; Bradley, T.; Budman, D.R. Novel microtubule-targeting agents - the epothilones. Biologics, 2008, 2(4), 789-811.
55. Goodin, S.; Kane, M.P.; Rubin, E.H. Epothilones: mechanism of action and biologic activity. J. Clin. Oncol., 2004, 22(10), 2015-2025.
56. Gapud, E.J.; Bai, R.; Ghosh, A.K.; Hamel, E. Laulimalide and paclitaxel: a comparison of their effects on tubulin assembly and their synergistic action when present simultaneously. Mol. Pharmacol, 2004, 66(1), 113-121.
57. Pineda, O.; Farras, J.; Maccari, L.; Manetti, F.; Botta, M.; Vilarrasa, J. Computational comparison of microtubule-stabilising agents laulimalide and peloruside with taxol and colchicine. Bioorg. Med. Chem. Lett., 2004, 74(19), 4825-4829.
58. Pera, B.; Razzak, M.; Trigili, C.; Pineda, O.; Canales, A.; Buey, R.M.; Jiménez-Barbero, J.; Northcote, P.T.; Paterson, I.; Barasoain, I.; Díaz, J.F. Molecular recognition of peloruside A by microtubules. The C24 primary alcohol is essential for biological activity. Chem Bio Chem, 2010, 77(12), 1669-1678.
59. Huzil, J.T.; Chik, J.K.; Slysz, G.W.; Freedman, H.; Tuszynski, J.; Taylor, R.E.; Sackett, D.L.; Schriemer, D.C. A unique mode of microtubule stabilization induced by peloruside A. J. Mol. Biol., 2008, 378(5), 1016-1030.
60. Kanakkanthara, A.; Wilmes, A.; O’Brate, A.; Escuin, D.; Chan, A.; Gjyrezi, A.; Crawford, J.; Rawson, P.; Kivell, B.; Northcote, P.T.; Hamel, E.; Giannakakou, P.; Miller, J.H. Peloruside- and laulimalide-resistant human ovarian carcinoma cells have pI-tubulin mutations and altered expression of pII- and pIII-tubulin isotypes. Mol. Cancer Ther., 2011, 70(8), 1419-1429.
61. Prota, A.E.; Bargsten, K.; Northcote, P.T.; Marsh, M.; Altmann, K.H.; Miller, J.H.; Díaz, J.F.; Steinmetz, M.O. Structural basis of microtubule stabilization by laulimalide and peloruside A. Angew. Chem. Int. Ed. Engl., 2014, 53(6), 1621-1625.
62. Khrapunovich-Baine, M.; Menon, V.; Yang, C.-P.; Northcote, P.T.; Miller, J.H.; Angeletti, R.H.; Fiser, A.; Horwitz, S.B.; Xiao, H. Hallmarks of molecular action of microtubule stabilizing agents: effects of epothilone B, ixabepilone, peloruside A, and laulimalide on microtubule conformation. J. Biol. Chem., 2011, 286(13), 11765-11778.
63. Rowinsky, E.K.; Eric, K. The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents. Ann. Rev Med., 1997, 48(1), 353-374.
64. Ojima, I.; Duclos, O.; Zucco, M.; Bissery, M.-C.; Combeau, C.; Vrignaud, P.; Riou, J.F.; Lavelle, F. Synthesis and structure-activity relationships of new antitumor taxoids. Effects of cyclohexyl substitution at the C-3 and/or C-2 of taxotere (docetaxel). J. Med. Chem., 1994, 37(16), 2602-2608.
65. Azarenko, O.; Smiyun, G.; Mah, J.; Wilson, L.; Jordan, M.A. Antiproliferative mechanism of action of the novel taxane cabazitaxel as compared with the parent compound docetaxel in MCF7 breast cancer cells. Mol. Cancer Ther., 2014, 73(8), 2092-2103.
66. Saif, M.W.; Sarantopoulos, J.; Patnaik, A.; Tolcher, A.W.; Takimoto, C.; Beeram, M. Tesetaxel, a new oral taxane, in combination with capecitabine: a phase I, dose-escalation study in patients with advanced solid tumors. Cancer Chemother. Pharmacol., 2011, 68(6), 1565-1573.
67. Diéras, V.; Limentani, S.; Romieu, G.; Tubiana-Hulin, M.; Lortholary, A.; Kaufman, P.; Girre, V.; Besenval, M.; Valero, V. Phase II multicenter study of larotaxel (XRP9881), a novel taxoid, in patients with metastatic breast cancer who previously received taxane-based therapy. Ann. Oncol., 2008, 79(7), 1255-1260.
68. Zatloukal, P.; Gervais, R.; Vansteenkiste, J.; Bosquee, L.; Sessa, C.; Brain, E.; Dansin, E.; Urban, T.; Dohollou, N.; Besenval, M.; Quoix, E. Randomized multicenter phase II study of larotaxel (XRP9881) in combination with cisplatin or gemcitabine as first line chemotherapy in nonirradiable stage IIIB or stage IV nonsmall cell lung cancer. J. Thorac. Oncol., 2008, 3(8), 894-901.
69. Fitzgerald, D.P.; Emerson, D.L.; Qian, Y.; Anwar, T.; Liewehr, D. J.; Steinberg, S.M.; Silberman, S.; Palmieri, D.; Steeg, P.S. TPI-287, a new taxane family member, reduces the brain metastatic colonization of breast cancer cells. Mol. Cancer Ther., 2012, 77(9), 1959-1967.
70. Chen, Q-H.; Kingston, D.G. Zampanolide and dactylolide: cytotoxic tubulin-assembly agents and promising anticancer leads. Nat Prod. Rep., 2014, 37(9), 1202-1226.
71. Guo, F.; Nimmanapalli, R.; Paranawithana, S.; Wittman, S.; Griffin, D.; Bali, P.; O’Bryan, E.; Fumero, C.; Wang, H.G.; Bhalla, K. Ectopic overexpression of second mitochondria-derived activator of caspases (Smac/DIABLO) or cotreatment with N-terminus of Smac/DIABLO peptide potentiates epothilone B derivative-(BMS 247550) and Apo-2L/TRAIL-induced apoptosis. Blood, 2002, 99(9), 3419-3426.
72. Abrey, L.; Wen, P.; Govindan, R.; Reimers, H.; Rigas, J.; Robins, H.; de Bedout, S.; O’Connell, C.; Li, X.; Johri, A. Activity of patupilone for the treatment of recurrent or progressive brain metastases in patients (pts) with non-small cell lung cancer (NSCLC): an open-label, multicenter, phase II study. J. Clin. Oncol., 2007, 25(18), Abstract No. 18058.
73. Colombo, N.; Kutarska, E.; Dimopoulos, M.; Bae, D.-S.; Rzepka-Gorska, I.; Bidzinski, M.; Scambia, G.; Engelholm, S.A.; Joly, F.; Weber, D.; El-Hashimy, M.; Li, J.; Souami, F.; Wing, P.; Engelholm, S.; Bamias, A.; Schwartz, P. Randomized, open-label, phase III study comparing patupilone (EPO906) with pegylated liposomal doxorubicin in platinum-refractory or -resistant patients with recurrent epithelial ovarian, primary fallopian tube, or primary peritoneal cancer. J. Clin. Oncol., 2012, 30(31), 3841-3847.
74. Lee, F.Y.; Borzilleri, R.; Fairchild, C.R.; Kim, S.-H.; Long, B.H.; Reventos-Suarez, C.; Vite, G.D.; Rose, W.C.; Kramer, R.A. BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy. Clin. Cancer Res., 2001, 7(5), 1429-1437.
75. Thomas, E.S.; Gomez, H.L.; Li, R.K.; Chung, H.-C.; Fein, L.E.; Chan, V.F.; Jassem, J.; Pivot, X.B.; Klimovsky, J.V.; de Mendoza, F. H.; Xu, B.; Campone, M.; Lerzo, G.L.; Peck, R.A.; Mukhopadhyay, P.; Vahdat, L.T.; Roché, H.H. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J. Clin. Oncol., 2007, 25(33), 5210-5217.
76. Risinger, A.L.; Mooberry, S.L. Taccalonolides: Novel microtubule stabilizers with clinical potential. Cancer Lett., 2010, 297(1), 1419.
77. Liu, J.; Towle, M.J.; Cheng, H.; Saxton, P.; Reardon, C.; Wu, J.; Murphy, E.A.; Kuznetsov, G.; Johannes, C.W.; Tremblay, M.R.; Zhao, H.; Pesant, M.; Fang, F.G.; Vermeulen, M.W.; Gallagher, B. M., Jr; Littlefield, B.A. In vitro and in vivo anticancer activities of synthetic (-)-laulimalide, a marine natural product microtubule stabilizing agent. Anticancer Res., 2007, 27(3B), 1509-1518.
78. Prota, A.E.; Bargsten, K.; Northcote, P.T.; Marsh, M.; Altmann, K.H.; Miller, J.H.; Díaz, J.F.; Steinmetz, M.O. Structural basis of microtubule stabilization by laulimalide and peloruside A. Angew. Chem. Int. Ed. Engl., 2014, 53(6), 1621-1625.
79. Kanakkanthara, A.; Eras, J.; Northcote, P.T.; Cabral, F.; Miller, J.H. Resistance to peloruside A and laulimalide: functional significance of acquired βI-tubulin mutations at sites important for drugtubulin binding. Curr. Cancer Drug Targets, 2014, 74(1), 79-90.
80. Hood, K.A.; West, L.M.; Rouwé, B.; Northcote, P.T.; Berridge, M.V.; Wakefield, S.J.; Miller, J.H. Peloruside A, a novel antimitotic agent with paclitaxel-like microtubule-stabilizing activity. Cancer Res., 2002, 62(12), 3356-3360.
81. Ravelli, R.B.; Gigant, B.; Curmi, P.A.; Jourdain, I.; Lachkar, S.; Sobel, A.; Knossow, M. Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain. Nature, 2004, 428(6979), 198-202.
82. Andreu, J.M.; Timasheff, S.N. Conformational states of tubulin liganded to colchicine, tropolone methyl ether, and podophyllotoxin. Biochemistry, 1982, 27(25), 6465-6476.
83. Brossi, A.; Yeh, H.J.; Chrzanowska, M.; Wolff, J.; Hamel, E.; Lin, C. M.; Quin, F.; Suffness, M.; Silverton, J. Colchicine and its analogues: recent findings. Med. Res. Rev., 1988, 8(1), 77-94.
84. Volbracht, C.; Leist, M.; Kolb, S.A.; Nicotera, P. Apoptosis in caspase-inhibited neurons. Mol. Med., 2001, 7(1), 36-48.
85. Sackett, D.L. Podophyllotoxin, steganacin and combretastatin: natural products that bind at the colchicine site of tubulin. Pharmacol. Ther., 1993, 59(2), 163-228.
86. Schilstra, M.J.; Martin, S.R.; Bayley, P.M. The effect of podophyl-lotoxin on microtubule dynamics. J. Biol. Chem., 1989, 264(15), 8827-8834.
87. Tozer, G.M.; Kanthou, C.; Parkins, C.S.; Hill, S.A. The biology of the combretastatins as tumour vascular targeting agents. Int. J. Exp. Pathol, 2002, 83(1), 21-38.
88. Lippert, J.W., III Vascular disrupting agents. Bioorg. Med. Chem., 2007, 75(2), 605-615.
89. Burridge, K.; Wennerberg, K. Rho and Rac take center stage. Cell, 2004, 776(2), 167-179.
90. Coderch, C.; Morreale, A.; Gago, F. Tubulin-based structure-affinity relationships for antimitotic Vinca alkaloids. Anti-Cancer Agent. Med. Chem., 2012, 72(3), 219-225.
91. Moudi, M.; Go, R.; Yien, C.Y.; Nazre, M. Vinca alkaloids. Int. J. Prev. Med., 2013, 4(11), 1231-1235.
92. Gigant, B.; Wang, C.; Ravelli, R.B.; Roussi, F.; Steinmetz, M.O.; Curmi, P.A.; Sobel, A.; Knossow, M. Structural basis for the regulation of tubulin by vinblastine. Nature, 2005, 435(7041), 519-522.
93. Negi, A.S.; Gautam, Y.; Alam, S.; Chanda, D.; Luqman, S.; Sarkar, J.; Khan, F.; Konwar, R. Natural antitubulin agents: importance of 3,4,5-trimethoxyphenyl fragment. Bioorg. Med. Chem., 2015, 25(3), 373-389.
94. Peterson, J.R.; Mitchison, T.J. Small molecules, big impact: a history of chemical inhibitors and the cytoskeleton. Chem. Biol., 2002, 9(12), 1275-1285.
95. Lu, Y.; Chen, J.; Xiao, M.; Li, W.; Miller, D.D. An overview of tubulin inhibitors that interact with the colchicine binding site. Pharm. Res., 2012, 29(11), 2943-2971.
96. Gaukroger, K.; Hadfield, J.A.; Lawrence, N.J.; Nolan, S.; McGown, A.T. Structural requirements for the interaction of combretastatins with tubulin: how important is the trimethoxy unit? Org. Biomol. Chem., 2003, 7(17), 3033-3037.
97. Rustin, G.J.; Shreeves, G.; Nathan, P.D.; Gaya, A.; Ganesan, T.S.; Wang, D.; Boxall, J.; Poupard, L.; Chaplin, D.J.; Stratford, M.R.; Balkissoon, J.; Zweifel, M. A Phase Ib trial of CA4P (combretastatin A-4 phosphate), carboplatin, and paclitaxel in patients with advanced cancer. Br. J. Cancer, 2010, 102(9), 1355-1360.
98. Sosa, J.A.; Elisei, R.; Jarzab, B.; Balkissoon, J.; Lu, S.P.; Bal, C.; Marur, S.; Gramza, A.; Yosef, R.B.; Gitlitz, B.; Haugen, B.R.; Ondrey, F.; Lu, C.; Karandikar, S.M.; Khuri, F.; Licitra, L.; Remick, S.C. Randomized safety and efficacy study of fosbretabulin with paclitaxel/carboplatin against anaplastic thyroid carcinoma. Thyroid, 2014, 24(2), 232-240.
99. Nathan, P.; Zweifel, M.; Padhani, A.R.; Koh, D.-M.; Ng, M.; Collins, D.J.; Harris, A.; Carden, C.; Smythe, J.; Fisher, N.; Taylor, N.J.; Stirling, J.J.; Lu, S.P.; Leach, M.O.; Rustin, G.J.; Judson, I. Phase I trial of combretastatin A4 phosphate (CA4P) in combination with bevacizumab in patients with advanced cancer. Clin. Cancer Res., 2012, 18(12), 3428-3439.
100. Greene, L.M.; Wang, S.; O’Boyle, N.M.; Bright, S.A.; Reid, J.E.; Kelly, P.; Meegan, M.J.; Zisterer, D.M. Combretazet-3 a novel synthetic cis-stable combretastatin A-4-azetidinone hybrid with enhanced stability and therapeutic efficacy in colon cancer. Oncol. Rep., 2013, 29(6), 2451-2458.
101. Johnson, S.P.; Ogunlade, O.; Zhang, E.; Lythgoe, M.; Beard, P.; Pedley, R.B. Abstract A08: Investigating tumor vasculature development and the effects of OXi4503 by non-invasive photoacoustic imaging. Cancer Res., 2015, 75(Suppl. 1), A08-A08.
102. Kim, T.J.; Ravoori, M.; Landen, C.N.; Kamat, A.A.; Han, L.Y.; Lu, C.; Lin, Y.G.; Merritt, W.M.; Jennings, N.; Spannuth, W.A.; Langley, R.; Gershenson, D.M.; Coleman, R.L.; Kundra, V.; Sood, A.K. Antitumor and antivascular effects of AVE8062 in ovarian carcinoma. Cancer Res., 2007, 67(19), 9337-9345.
103. Yamazaki, Y.; Sumikura, M.; Hidaka, K.; Yasui, H.; Kiso, Y.; Yakushiji, F.; Hayashi, Y. Anti-microtubule plinabulin chemical probe KPU-244-B3 labeled both a and β-tubulin. Bioorg. Med. Chem., 2010, 18(9), 3169-3174.
104. Millward, M.; Mainwaring, P.; Mita, A.; Federico, K.; Lloyd, G.K.; Reddinger, N.; Nawrocki, S.; Mita, M.; Spear, M.A. Phase 1 study of the novel vascular disrupting agent plinabulin (NPI-2358) and docetaxel. Invest. New Drugs, 2012, 30(3), 1065-1073.
105. Mita, A.; Heist, R.; Aren, O.; Mainwaring, P.; Bazhenova, L.; Gadgeel, S.; Blum, R.; Polikoff, J.; Biswas, J.; Spear, M. Phase II study of docetaxel with or without plinabulin (NPI-2358) in patients with non-small cell lung cancer (NSCLC). J. Clin. Oncol., 2010, 28(15), Abstract No. 7592.
106. Breuleux, M.; Bachmann, F.; Pohlmann, J.; Mathews, S.; Burger, K.; Kellenberger, L.; Lane, H. Phase I clinical trial of MPC-6827 (Azixa), a microtubule destabilizing agent, in patients with advanced cancer. Mol. Cancer Ther., 2010, 9(12), 3410-3419.
107. Kasibhatla, S.; Baichwal, V.; Cai, S.X.; Roth, B.; Skvortsova, I.; Skvortsov, S.; Lukas, P.; English, N.M.; Sirisoma, N.; Drewe, J.; Pervin, A.; Tseng, B.; Carlson, R.O.; Pleiman, C.M. MPC-6827: a small-molecule inhibitor of microtubule formation that is not a substrate for multidrug resistance pumps. Cancer Res., 2007, 67(12), 5865-5871.
108. Tsimberidou, A.-M.; Akerley, W.; Schabel, M.C.; Hong, D.S.; Uehara, C.; Chhabra, A.; Warren, T.; Mather, G.G.; Evans, B.A.; Woodland, D.P.; Swabb, E.A.; Kurzrock, R. Phase I clinical trial of MPC-6827 (Azixa), a microtubule destabilizing agent, in patients with advanced cancer. Mol. Cancer Ther., 2010, 9(12), 3410-3419.
109. Field, J.J.; Kanakkanthara, A.; Miller, J.H. Microtubule-targeting agents are clinically successful due to both mitotic and interphase impairment of microtubule function. Bioorg. Med. Chem., 2014, 22(18), 5050-5059.
110. Retz, M.; de Geeter, P.; Goebell, P.J.; Matz, U.; de Schultz, W.; Hegele, A. Vinflunine in routine clinical practice for the treatment of advanced or metastatic urothelial cell carcinoma data from a prospective, multicenter experience. BMC Cancer, 2015, 75(1), 455.
111. Morris, R.T.; Joyrich, R.N.; Naumann, R.W.; Shah, N.P.; Maurer, A.H.; Strauss, H.W.; Uszler, J.M.; Symanowski, J.T.; Ellis, P.R.; Harb, W.A. Phase II study of treatment of advanced ovarian cancer with folate-receptor-targeted therapeutic (vintafolide) and companion SPECT-based imaging agent (99mTc-etarfolatide). Ann. Oncol., 2014, 25(4), 852-858.
112. Dumontet, C.; Jordan, M.A. Microtubule-binding agents: a dynamic field of cancer therapeutics. Nat. Rev. Drug Discov., 2010, 9(10), 790-803.
113. Bates, S.E.; Eisch, R.; Ling, A.; Rosing, D.; Turner, M.; Pittaluga, S.; Prince, H.M.; Kirschbaum, M.H.; Allen, S.L.; Zain, J.; Geskin, L.J.; Joske, D.; Popplewell, L.; Cowen, E.W.; Jaffe, E.S.; Nichols, J.; Kennedy, S.; Steinberg, S.M.; Liewehr, D.J.; Showe, L.C.; Steakley, C.; Wright, J.; Fojo, T.; Litman, T.; Piekarz, R.L. Romidepsin in peripheral and cutaneous T-cell lymphoma: mechanistic implications from clinical and correlative data. Br. J. Haematol., 2015, 770(1), 96-109.
114. Gamucci, T.; Michelotti, A.; Pizzuti, L.; Mentuccia, L.; Landucci, E.; Sperduti, I.; Di Lauro, L.; Fabi, A.; Tonini, G.; Sini, V.; Salesi, N.; Ferrarini, I.; Vaccaro, A.; Pavese, I.; Veltri, E.; Moscetti, L.; Marchetti, P.; Vici, P. Eribulin mesylate in pretreated breast cancer patients: a multicenter retrospective observational study. J. Cancer, 2014, 5(5), 320-327.
115. Prota, A.E.; Bargsten, K.; Diaz, J.F.; Marsh, M.; Cuevas, C.; Liniger, M.; Neuhaus, C.; Andreu, J.M.; Altmann, K.-H.; Steinmetz, M.O. A new tubulin-binding site and pharmacophore for microtubule-destabilizing anticancer drugs. Proc. Natl. Acad. Sci. USA, 2014, 777(38), 13817-13821.
116. Martín, M.J.; Coello, L.; Fernández, R.; Reyes, F.; Rodríguez, A.; Murcia, C.; Garranzo, M.; Mateo, C.; Sánchez-Sancho, F.; Bueno, S.; de Eguilior, C.; Francesch, A.; Munt, S.; Cuevas, C. Isolation and first total synthesis of PM050489 and PM060184, two new marine anticancer compounds. J. Am. Chem. Soc., 2013, 755(27), 10164-10171.
117. Martínez-Díez, M.; Guillén-Navarro, M.J.; Pera, B.; Bouchet, B.P.; Martínez-Leal, J.F.; Barasoain, I.; Cuevas, C.; Andreu, J.M.; García-Fernández, L.F.; Díaz, J.F.; Avilés, P.; Galmarini, C.M. PM060184, a new tubulin binding agent with potent antitumor activity including P-glycoprotein over-expressing tumors. Biochem. Pharmacol, 2014, (3), 291-302.
118. Pera, B.; Barasoain, I.; Pantazopoulou, A.; Canales, A.; Matesanz, R.; Rodriguez-Salarichs, J.; García-Fernandez, L.F.; Moneo, V.; Jiménez-Barbero, J.; Galmarini, C.M.; Cuevas, C.; Peñalva, M.A.; Díaz, J.F.; Andreu, J.M. New interfacial microtubule inhibitors of marine origin, PM050489/PM060184, with potent antitumor activity and a distinct mechanism. ACS Chem. Biol., 2013, 8(9), 2084-2094.
119. Hanauske, A.R.; Catimel, G.; Aamdal, S.; ten Bokkel Huinink, W.; Paridaens, R.; Pavlidis, N.; Kaye, S.B.; te Velde, A.; Wanders, J.; Verweij, J. Phase II clinical trials with rhizoxin in breast cancer and melanoma. Br. J. Cancer, 1996, 75(3), 397-399.
120. Lopus, M.; Oroudjev, E.; Wilson, L.; Wilhelm, S.; Widdison, W.; Chari, R.; Jordan, M.A. Maytansine and cellular metabolites of antibody-maytansinoid conjugates strongly suppress microtubule dynamics by binding to microtubules. Mol. Cancer Ther., 2010, 9(10), 2689-2699.
121. Singer, W.D.; Jordan, M.A.; Wilson, L.; Himes, R.H. Binding of vinblastine to stabilized microtubules. Mol. Pharmacol., 1989, 56(3), 366-370.
122. Roach, M.C.; Ludueña, R.F. Different effects of tubulin ligands on the intrachain cross-linking of beta 1-tubulin. J. Biol. Chem., 1984, 259(19), 12063-12071.
123. Oroudjev, E.; Lopus, M.; Wilson, L.; Audette, C.; Provenzano, C.; Erickson, H.; Kovtun, Y.; Chari, R.; Jordan, M.A. Maytansinoid antibody conjugates induce mitotic arrest by suppressing microtubule dynamic instability. Mol. Cancer Ther., 2010, 9(10), 2700-2713.
124. Lai, K.C.; Deckert, J.; Setiady, Y.Y.; Shah, P.; Wang, L.; Chari, R.; Lambert, J.M. Evaluation of targets for maytansinoid ADC therapy using a novel radiochemical Assay. Pharm. Res., 2015, 32(11), 3593-3603.
125. Coiffier, B.; Ribrag, V.; Dupuis, J.; Tilly, H.; Haioun, C.; Morschhauser, F.; Lamy, T.; Copie-Bergman, C.; Brehar, O.; Houot, R. Phase I/II study of the anti-CD19 maytansinoid immuno conjugate SAR3419 administered weekly to patients (pts) with relapsed/refractory B-cell non-Hodgkin lymphoma (NHL). J. Clin. Oncol., 2011, 29(15), Abstract No. 8017.
126. Whiteman, K.R.; Johnson, H.A.; Xu, S.; Carrigan, C.N.; Ab, O.; Pinkas, J. Preclinical evaluation of IMGN853, an anti-FOLR1 antibody-maytansinoid conjugate, as a potential therapeutic for ovarian cancer. Cancer Res., 2011, 71(Suppl. 8), 1760-1760.
127. Borghaei, H.; O’Malley, D.M.; Seward, S.M.; Bauer, T.M.; Perez, R.P.; Oza, A.M.; Jeong, W.; Michenzie, M.F.; Kirby, M.W.; Chandorkar, G. Phase 1 study of IMGN853, a folate receptor alpha (FR {alpha})-targeting antibody-drug conjugate (ADC) in patients (Pts) with epithelial ovarian cancer (EOC) and other FRA-positive solid tumors. J. Clin. Oncol., 2015, 33, Abstract No. 5558.
128. Bai, R.L.; Pettit, G.R.; Hamel, E. Binding of dolastatin 10 to tubulin at a distinct site for peptide antimitotic agents near the exchangeable nucleotide and vinca alkaloid sites. J. Biol. Chem., 1990, 265(28), 17141-17149.
129. Perez, E.A.; Hillman, D.W.; Fishkin, P.A.; Krook, J.E.; Tan, W.W.; Kuriakose, P.A.; Alberts, S.R.; Dakhil, S.R. Phase II trial of dolastatin-10 in patients with advanced breast cancer. Invest. New Drugs, 2005, 23(3), 257-261.
130. Bai, R.; Taylor, G.F.; Cichacz, Z.A.; Herald, C.L.; Kepler, J.A.; Pettit, G.R.; Hamel, E. The spongistatins, potently cytotoxic inhibitors of tubulin polymerization, bind in a distinct region of the vinca domain. Biochemistry, 1995, 34(30), 9714-9721.
131. Kobayashi, S.; Tsuchiya, K.; Harada, T.; Nishide, M.; Kurokawa, T.; Nakagawa, T.; Shimada, N.; Kobayashi, K. Pironetin, a novel plant growth regulator produced by Streptomyces sp. NK10958. I. Taxonomy, production, isolation and preliminary characterization. J. Antibiot., 1994, 47(6), 697-702.
132. Kondoh, M.; Usui, T.; Kobayashi, S.; Tsuchiya, K.; Nishikawa, K.; Nishikiori, T.; Mayumi, T.; Osada, H. Cell cycle arrest and antitumor activity of pironetin and its derivatives. Cancer Lett., 1998, 126(1), 29-32.
133. Kondoh, M.; Usui, T.; Nishikiori, T.; Mayumi, T.; Osada, H. Apoptosis induction via microtubule disassembly by an antitumour compound, pironetin. Biochem. J., 1999, 340(Pt 2), 411-416.
134. Yang, J.; Wang, Y.; Wang, T.; Jiang, J.; Botting, C.H.; Liu, H.; Chen, Q.; Yang, J.; Naismith, J.H.; Zhu, X.; Chen, L. Pironetin reacts covalently with cysteine-316 of a-tubulin to destabilize microtubule. Nat. Commun., 2016, 7, 12103.
135. Prota, A.E.; Setter, J.; Waight, A.B.; Bargsten, K.; Murga, J.; Diaz, J.F.; Steinmetz, M.O. Pironetin binds covalently to aCys316 and perturbs a major loop and helix of a-tubulin to inhibit microtubule formation. J. Mol. Biol., 2016, 428(15), 2981-2988.
136. Yoshida, M.; Matsui, Y.; Ikarashi, Y.; Usui, T.; Osada, H.; Wakasugi, H. Antiproliferating activity of the mitotic inhibitor pironetin against vindesine and paclitaxel-resistant human small cell lung cancer H69 cells. Anticancer Res., 2007, 27(2), 729-736.
137. Skvortsova, I.; Debbage, P.; Kumar, V.; Skvortsov, S. Radiation resistance: cancer stem cells (CSCs) and their enigmatic prosurvival signaling. Semin. Cancer Biol., 2015, 35, 39-44.